The EU's approval of the first long-acting HIV injection therapy could reduce the number of treatments per year to six

The use of antiviral "cocktail" therapy to treat HIV infection is one of the most important advances in medicine over the past 25 years.
there are already a variety of effective control of HIV-1 virus proliferation of single-piece combination treatment options, as long as patients adhere to daily medication, their life expectancy and healthy people are not significantly different.
, however, if patients are unable to take their medication daily for some reason, the virus may not only return, but also increase the risk of developing resistance.
before the birth of healing therapy, daily medication was still a burden for many people living with HIV.
is an oral non-nucleoside retrovirase inhibitor.
is an integrated enzyme inhibitor that inhibits the integration of viral DNA into the genomes of human immune cells.
integration step is an indispensable step in the HIV replication process and an important cause of chronic infection.
capote and lipieverin injections are given once a month or once every 2 months, and are given twice intramuscular injections by health care professionals at the same time.
injections, patients need to take oral tablets of cabotvir and lippivirin for about 1 month to assess the drug's tolerance.
application for the new drug is based on positive results from key Phase 3 clinical trials at ATLAS, FLAIR and ATLAS-2M.
at ATLAS and FLAAIR included more than 1,100 subjects from 16 countries.
these studies showed that one intra hip intramyal injection of cabotway and lipivirin per month was just as effective at maintaining viral inhibition as continuing oral antiretroviral therapy once a day during the 48-week study period.
at ATLAS and FLAR, about 9 out of 10 patients were more likely to convert to cabotway and lipivellin long-acting treatments than in previous daily oral treatments.
data from key ATLAS-2M trials show that the antiviral activity and safety of kabotvir and lipivirin long-acting injections every 2 months meet non-inferior performance standards compared to monthly dosing.
resources: s1 . Retrieved December 22, 2020, from。